Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) --  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies, today announced the appointment of Jennifer Fox as its Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., Ph. D as Head of Research and Development and Chief Medical Officer.

“We are thrilled to welcome Tanya and Jen to our executive team,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “Tanya is a deeply experienced physician-scientist leader and Jen is a seasoned healthcare finance and corporate development leader. With their decades of industry leadership experience, they will each be an invaluable addition to Zenas as we head into our next phase of growth, advancing multiple global programs in late-stage clinical development with a goal to deliver differentiated I&I directed therapies to patients in need around the world.”

Ms. Fox is an experienced finance and corporate development executive with an extensive track record in corporate finance and healthcare investment banking, advising numerous private and public companies with respect to strategy, financings and mergers and acquisitions. Prior to joining Zenas, Ms. Fox served as Chief Financial Officer at Nuvation Bio, a publicly traded biotechnology company. She previously served as a Managing Director and Co-Head of North America Healthcare Corporate and Investment Banking Group at CitiGroup. Prior to CitiGroup, Ms. Fox held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America and Prudential Securities. She holds B.S. degrees in finance and marketing from Manhattan College.

Dr. Fischer is a physician-scientist with deep experience in academia and at both pharmaceutical and biotechnology companies, leading early and late-stage research and development programs across multiple therapeutic areas, including neurology and rare diseases. Prior to joining Zenas, she served as Chief Development Officer and Head of Translational Medicine at Biohaven, a publicly traded biopharmaceutical company. Dr. Fischer began her industry career at Bristol Myers Squibb and held R&D leadership roles of increasing responsibility at EMD-Serono, Sanofi-Genzyme and Alnylam. She is a neurologist and held appointments at Yale University School of Medicine following the completion of her Neurology residency at Yale New Haven Hospital. She obtained MD and PhD degrees from the University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School and Rutgers University, respectively, and was awarded the prestigious Presidential Early Career Award for Scientists and Engineers (PECASE).

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies, including in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc. Obexelimab is currently being studied in a global Phase 3 clinical study in patients with IgG4 Related Disease and a global Phase2/3 study in patients with warm autoimmune hemolytic anemia (wAIHA). Clinical development of obexelimab for Multiple Sclerosis and Systemic Lupus Erythematosus is under evaluation.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 3 (SApHiAre) study for the treatment of wAIHA is available at clinicaltrials.gov: NCT05786573.


Investor and Media Contact: Joe Farmer, President & COO Zenas BioPharma IR@zenasbio.com  


Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

THỦ THUẬT HAY

5 cách giúp smartphone kết nối 4G nhanh

Trong nhiều trường hợp, mạng 4G sẽ là cứu cánh của bạn khi kết nối Wifi bị ngắt hay không đảm bảo. Để có thể sử dụng hiệu quả chúng, bạn hãy tham khảo một vài cách giúp smartphone kết nối 4G nhanh và đơn giản dưới đây.

Bảo mật 2 lớp: Công cụ mạnh để bảo vệ tài khoản nhưng ít ai dùng

Bảo mật 2 lớp, 2FA (2-factor authentication), là một công cụ giúp cho việc bảo vệ tài khoản được tốt hơn bằng cách thêm một thao tác yêu cầu nhập mã xác nhận trước khi đăng nhập thành công. Không phải ngẫu nhiên mà các

iPhone của bạn vừa mượt vừa tiết kiệm 3G hơn chỉ với một thao tác sau

Background App Refresh hay còn gọi là Làm mới ứng dụng nền là tính năng được rất nhiều chuyên gia khuyên bạn tắt đi khi sử dụng iPhone để tiết...

Làm thế nào để thay đổi độ sáng màn hình máy tính?

Nhìn vào bàn phím máy tính của bạn hàng F1 đến F12, bạn sẽ thấy 2 phím có biểu tượng mặt trời, phím có biểu tượng mặt trời và mũi tên hướng lên trên là nút tăng độ sáng màn hình, nút có biểu tượng mặt trời và mũi tên

Những sai lầm phổ biến khi sạc điện thoại

Sai lầm khi sạc pin sẽ khiến pin nhanh hỏng, việc sạc pin điện thoại đúng cách không chỉ giúp pin bền hơn mà còn giúp máy hoạt động ổn định hơn. Nếu bạn đang mắc phải những lỗi sạc pin điện thoại phổ biến này thì nên

ĐÁNH GIÁ NHANH

Đánh giá thời lượng pin thực tế của Galaxy S7

Đánh giá chính xác nhất thời lượng pin thực tế của Galaxy S7/S7 edge thông qua các tác vụ như: duyệt web qua Wi-Fi, chạy video và để thiết bị trong chế độ chờ.

Đánh giá pin Philips S616 - Ấn tượng trong tầm giá

Được trang bị viên pin có dung lượng 3000 mAh, Philips S616 cho thời lượng sử dụng ấn tượng so với các sản phẩm khác trong tầm giá.